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Purpose/Objective: The incidence of rectal cancer in 
Pakistan is similar to those in other Asian countries, but much 
lower than in the developed countries. At present, the risk is 
equal in both sexes. However a 41% rise in incidence was 
noted in Pakistani males during the period 1995-1999, which 
may indicate a higher risk in males in the future. Most rectal 
cancers present at advanced stages, and are not amenable to 
upfront curative surgery 
The aim of this is study is to observe the Benefits of high-
dose-rate intraluminal brachytherapy for rectal Cancers 
during preoperative chemo radiation. 
Materials and Methods: Between 2009 and 2011, Seventy-
two patients with locally advanced rectal cancer (≥ T3 or 
N+), were treated initially with concurrent capecitabine (825 
mg/m2 oral twice daily) and pelvic external beam 
radiotherapy (EBRT) (45 Gy in 25 fractions), then were 
randomized to group A; HDR ILBT group (n = 34) to receive 
5.5-7 Gy × 2 to gross tumor volume (GTV) and group B; EBRT 
group (n = 38) to receive 5.4 Gy × 3 fractions to GTV with 
EBRT 
Results: All patients underwent total mesorectal excision. 
Grade 3 acute toxicities were registered in 24 patients 
(70.6%) in group A and in 16 (42.1%) in group B. Complete 
pathologic response of T stage (ypT0) in group A was 
registered in 20 patients (58.8%) and in group B, 6 patients 
(15.8%) had ypT0 (P < 0.0001). Sphincter preservation was 
reported in 12/18 patients (66.7%) in group A and in 10/20 
patients (50%) in group B (P < 0.01). Overall radiological 
response was 68.15% and 66.04% in Group A and B, 
respectively. During a median follow up of 18 mo, late grade 
1 and 2 sequelae were registered in 6 patients (17.6%) and 8 
patients (21.1%) in the groups A and B, respectively. 
Conclusions: From the study it is concluded that HDR-ILBT 
found to be effective dose escalation technique in 
preoperative chemoradiation for rectal cancers, with higher 
response rates, down staging and with manageable acute 
toxicities. 
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Purpose/Objective: This study aimed to use deformable 
image registration (DIR) to account for anatomical 
differences between each phase of a combined external 
beam (EBRT)/HDR brachytherapy prostate treatment and to 
allow the planned dose distributions to be combined. The 
objective was to extract reliable dose-volume parameters for 
correlation against recoded treatment toxicities. 
Materials and Methods: 93 prostate cancer patients, accrued 
to the RADAR trial, received EBRT in 23 fractions of 2 Gy and 
HDR in 3 fractions of 6.5 Gy, with dose distribution calculated 
using the TG43 dose algorithm (replanned with the Acuros 
dose algorithm). The EBRT CT scan was registered to the HDR 
CT scan with rigid registration followed by a deformable 
multi-pass method (RD) in Velocity Advanced Imaging. 
Additionally, a rigid plus scale plus deformable multi-pass 
(RSD) method was used. The unregistered EBRT, 
unregistered/registered TG43 HDR and 
unregistered/registered Acuros HDR dose distributions were 
converted to equieffective doses at 2 Gy/fraction. Alpha-
beta ratios of 3 and 5 were used. The rectum total D2cc was 
calculated in two alternative ways. (1) Parameter adding: the 
D2cc value from the unregistered EQD2α/β EBRT dose 
distribution was added to the D2cc from the unregistered 
EQD2α/β HDR dose distribution. (2) Distribution adding: the 
unregistered EQD2α/β EBRT dose distribution was summed 
voxel-by-voxel with the registered EQD2α/β HDR dose 
distribution and then the total D2cc was extracted. The 
pairwise percentage differences between the D2cc values for 
the calculation methods were assessed via exact Wilcoxon 
singed-rank tests against a median percentage difference of 
zero. 
Results: The figure provides the rectum D2cc values for 
parameter and distribution adding with the TG43 dose 
algorithm and an alpha-beta ratio of 3. The maximum D2cc 
values were larger for distribution adding after either 
registration method relative to the parameter adding values. 
The pairwise percentage difference between rectum D2cc 
values for various parameter adding versus distribution 
adding comparisons were negative and significant (p<0.05, 
see table). 
 
 
 
Conclusions: Applying registrations resulted in significantly 
different D2cc values relative to summing the planned D2cc 
values without registration. The percentage differences were 
low and the registration methods varied in terms of the final 
location of the anterior rectum surface relative to the HDR 
needles (e.g. the maximum D2cc). Consequently, careful 
grouping of the accuracy/adequacy of the registrations is 
being undertaken before concluding the registrations lead to 
greater D2cc values compared to parameter adding.  
